These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 31872456)

  • 21. Ustekinumab in patients previously treated with TNFα inhibitors: a real-life study.
    Pinheiro RR; Duarte B; Ferreira A; Cabete J
    Eur J Dermatol; 2018 Feb; 28(1):89-91. PubMed ID: 29400282
    [No Abstract]   [Full Text] [Related]  

  • 22. Gene Signatures of Early Response to Anti-TNF Drugs in Pediatric Inflammatory Bowel Disease.
    Salvador-Martín S; Raposo-Gutiérrez I; Navas-López VM; Gallego-Fernández C; Moreno-Álvarez A; Solar-Boga A; Muñoz-Codoceo R; Magallares L; Martínez-Ojinaga E; Fobelo MJ; Millán-Jiménez A; Rodriguez-Martinez A; Vayo CA; Sánchez C; Tolin M; Bossacoma F; Pujol-Muncunill G; González de Caldas R; Loverdos I; Blanca-García JA; Segarra O; Eizaguirre FJ; García-Romero R; Merino-Bohórquez V; Sanjurjo-Sáez M; López-Fernández LA
    Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32397546
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of tumor necrosis factor-α, interleukin-23 and interleukin-17A inhibitors on bodyweight and body mass index in patients with psoriasis.
    Takamura S; Takahashi A; Inoue Y; Teraki Y
    J Dermatol; 2018 Sep; 45(9):1130-1134. PubMed ID: 30004583
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of rs610604 in TNFAIP3 and rs17728338 in TNIP1 gene polymorphisms with psoriasis susceptibility: a meta-analysis of case-control studies.
    Gong HB; Gao ST; Pu XM; Kang XJ; Wu XJ
    BMC Med Genet; 2020 May; 21(1):103. PubMed ID: 32398022
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The relationship between tumour necrosis factor (TNF)-α promoter and IL12B/IL-23R genes polymorphisms and the efficacy of anti-TNF-α therapy in psoriasis: a case-control study.
    Gallo E; Cabaleiro T; Román M; Solano-López G; Abad-Santos F; García-Díez A; Daudén E
    Br J Dermatol; 2013 Oct; 169(4):819-29. PubMed ID: 23662788
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination of antitumour necrosis factor-α and anti-interleukin-12/23 antibodies in refractory psoriasis and psoriatic arthritis: a long-term case-series observational study.
    Gniadecki R; Bang B; Sand C
    Br J Dermatol; 2016 May; 174(5):1145-6. PubMed ID: 26522308
    [No Abstract]   [Full Text] [Related]  

  • 27. The tumor necrosis factor receptor superfamily member 1B polymorphisms predict response to anti-TNF therapy in patients with autoimmune disease: A meta-analysis.
    Chen W; Xu H; Wang X; Gu J; Xiong H; Shi Y
    Int Immunopharmacol; 2015 Sep; 28(1):146-53. PubMed ID: 26071216
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gene polymorphisms of TNF-238G/A, TNF-308G/A, IL10-1082G/A, TNFAIP3, and MC4R and comorbidity occurrence in a Romanian population with psoriasis.
    Voiculescu VM; Solomon I; Popa A; Draghici CC; Dobre M; Giurcaneanu C; Papagheorghe LML; Lupu M
    J Med Life; 2018; 11(1):69-74. PubMed ID: 29696068
    [No Abstract]   [Full Text] [Related]  

  • 29. Association of TNF-α, TNFRSF1A and TNFRSF1B gene polymorphisms with the risk of sporadic breast cancer in northeast Chinese Han women.
    Xu F; Zhou G; Han S; Yuan W; Chen S; Fu Z; Li D; Zhang H; Li D; Pang D
    PLoS One; 2014; 9(7):e101138. PubMed ID: 25010932
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic drug monitoring of patients with psoriasis during tumour necrosis factor (TNF)-α antagonist treatment using a novel interleukin-8 reporter cell line.
    Kimura Y; Shimada-Omori R; Takahashi T; Tsuchiyama K; Kusakari Y; Yamasaki K; Nishikawa R; Nishigori C; Aiba S
    Br J Dermatol; 2016 Nov; 175(5):979-987. PubMed ID: 27155194
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical predictors of nonresponse to anti-TNF-α agents in psoriatic patients: A retrospective study.
    De Simone C; Caldarola G; Maiorino A; Tassone F; Campana I; Sollena P; Peris K
    Dermatol Ther; 2016 Sep; 29(5):372-376. PubMed ID: 27146358
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New polymorphisms associated with response to anti-TNF drugs in patients with moderate-to-severe plaque psoriasis.
    Prieto-Pérez R; Solano-López G; Cabaleiro T; Román M; Ochoa D; Talegón M; Baniandrés O; López-Estebaranz JL; de la Cueva P; Daudén E; Abad-Santos F
    Pharmacogenomics J; 2018 Jan; 18(1):70-75. PubMed ID: 27670765
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor-α inhibitors versus methotrexate.
    Wu JJ; Guérin A; Sundaram M; Dea K; Cloutier M; Mulani P
    J Am Acad Dermatol; 2017 Jan; 76(1):81-90. PubMed ID: 27894789
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-TNF agents and nail psoriasis: a single-center, retrospective, comparative study.
    Kyriakou A; Patsatsi A; Sotiriadis D
    J Dermatolog Treat; 2013 Jun; 24(3):162-8. PubMed ID: 22136334
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Management of severe psoriasis with TNF antagonists. Adalimumab, etanercept and infliximab.
    Mössner R; Reich K
    Curr Probl Dermatol; 2009; 38():107-136. PubMed ID: 19710553
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor necrosis factor (TNF) inhibitors revolutionalized therapy for both psoriasis and psoriatic arthritis. Foreword.
    Gottlieb AB
    Am J Clin Dermatol; 2014 Feb; 15 Suppl 1():S3-4. PubMed ID: 24777570
    [No Abstract]   [Full Text] [Related]  

  • 37. Survival rate of antitumour necrosis factor-α treatments for psoriasis in routine dermatological practice: a multicentre observational study.
    Esposito M; Gisondi P; Cassano N; Ferrucci G; Del Giglio M; Loconsole F; Giunta A; Vena GA; Chimenti S; Girolomoni G
    Br J Dermatol; 2013 Sep; 169(3):666-72. PubMed ID: 23647206
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biologic drug survival in Israeli psoriasis patients.
    Shalom G; Cohen AD; Ziv M; Eran CB; Feldhamer I; Freud T; Berman E; Oren S; Hodak E; Pavlovsky L
    J Am Acad Dermatol; 2017 Apr; 76(4):662-669.e1. PubMed ID: 28038888
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The polymorphism rs763780 in the IL-17F gene is associated with response to biological drugs in patients with psoriasis.
    Prieto-Pérez R; Solano-López G; Cabaleiro T; Román M; Ochoa D; Talegón M; Baniandrés O; López Estebaranz JL; de la Cueva P; Daudén E; Abad-Santos F
    Pharmacogenomics; 2015; 16(15):1723-31. PubMed ID: 26415694
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetic polymorphism predicting Methotrexate efficacy in Chinese patients with psoriasis vulgaris.
    Kuang YH; Lu Y; Yan KX; Liu PP; Chen WQ; Shen MX; He YJ; Wu LS; Qin QS; Zhou XC; Li J; Su J; zhiLv C; Zhu W; Chen X
    J Dermatol Sci; 2019 Jan; 93(1):8-13. PubMed ID: 30563733
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.